Search

Displaying results 2361 - 2370 of 7503 in total
  1. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011. … The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis.

  2. Drug

    Fencamfamin

    go.drugbank.com/drugs/DB01463
    ApprovedIllicitWithdrawn

    It is especially useful in patients with chronic conditions due to its favourable safety profile. … It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose.

  3. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.

    Categories: Estrogens, Non-Steroidal
  4. Drug

    Entacapone

    go.drugbank.com/drugs/DB00494
    ApprovedInvestigational

    Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. … When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration

    Mixtures: LEVOCAENT-NX 100/25/200, LEVOCAENT-NX 100/25/200Synonyms: (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide, N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
  5. Drug

    Alogliptin

    go.drugbank.com/drugs/DB06203
    ApprovedInvestigational

    It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.

  6. Drug

    Zoledronic acid

    go.drugbank.com/drugs/DB00399
    ApprovedInvestigational

    [A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712] … Zoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid].

  7. Drug

    Abatacept

    go.drugbank.com/drugs/DB01281
    ApprovedInvestigational

    The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. … Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human

  8. Drug

    Azatadine

    go.drugbank.com/drugs/DB00719
    ApprovedWithdrawn

    Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells.

    Mixtures: CO-TYLENOL
  9. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. … [L9392] The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated.

  10. Drug

    rhMBL

    go.drugbank.com/drugs/DB05237
    Investigational

    MBL forms different oligomers but must form at least a tetramer to be active. … rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).